Get the Stockscreener App
2.80
0.36%
-0.01
Polypid Ltd stock is traded at $2.80, with a volume of 14,687.
It is down -0.36% in the last 24 hours and up +1.82% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$2.81
Open:
$2.848
24h Volume:
14,687
Relative Volume:
0.81
Market Cap:
$28.43M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.1423
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
+2.00%
1M Performance:
+1.82%
6M Performance:
-21.02%
1Y Performance:
-39.85%
1-Day Range:
$2.78
$2.848
1-Week Range:
$2.6804
$3.28
52-Week Range:
$2.30
$4.67
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
2.79 | 29.04M | 0 | -23.87M | -47.63M | -19.67 |
|
ONC
Beigene Ltd Adr
|
238.32 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.69 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.43 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.00 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid chairman to step down at June shareholder meeting By Investing.com - Investing.com Nigeria
PolyPid chairman to step down at June shareholder meeting - Investing.com Australia
PolyPid Announces Leadership Changes Ahead of June 2025 Shareholder Meeting - TipRanks
PolyPid Opens Virtual Access to Investors: Key Presentation and 1-on-1 Meetings at Lytham Conference - Stock Titan
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - GlobeNewswire
Head to Head Survey: PolyPid (NASDAQ:PYPD) & Lombard Medical (OTCMKTS:EVARF) - Defense World
Tenon Medical (NASDAQ:TNON) vs. PolyPid (NASDAQ:PYPD) Critical Comparison - Defense World
PolyPid Ltd. Earnings Call: Progress and Challenges - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript - Insider Monkey
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
PolyPid Ltd. Reports Q1 2025 Results and Trial Progress - TipRanks
Polypid Q1 Net Income USD -8.3 Million - marketscreener.com
PolyPid (PYPD) Prepares for Transformational 2025 with Promising - GuruFocus
PolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100 - TipRanks
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Transcript : PolyPid Ltd., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PolyPid (PYPD) Expected to Announce Earnings on Wednesday - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update - Defense World
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 - GlobeNewswire
PolyPid Q1 2025 Earnings Preview: Surgical Outcomes Biopharma Reports May 14 - Stock Titan
Reviewing Baxter International (NYSE:BAX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid to Participate in The Citizens Life Sciences Conference - GlobeNewswire
PolyPid to Reveal Next-Gen Surgical Innovation Pipeline at Elite Citizens Life Sciences Conference - Stock Titan
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 25.9% - Defense World
What is HC Wainwright’s Estimate for PolyPid Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for PolyPid Q1 Earnings? - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target - Investing.com Australia
PolyPid’s (PYPD) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on PolyPid stock with $11 target By Investing.com - Investing.com Canada
PolyPid stock touches 52-week low at $2.32 amid market challenges By Investing.com - Investing.com South Africa
PolyPid stock touches 52-week low at $2.32 amid market challenges - Investing.com Australia
Surgical Site Infections Clinical and Non-Clinical Studies, - openPR.com
Barclays Reaffirms Their Hold Rating on PolyPid (PYPD) - The Globe and Mail
Comparing Beta Bionics (NASDAQ:BBNX) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - Yahoo
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.37%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):